• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Snow Peas International, Inc. 20-Sep-01


Public Health Service

Food and Drug Administration
555 Winderley Place, Suite 200
Maitland, FL 32751

September 20, 2001

Ref Customs Entry No. BF3-0002628-8/00l/00l
Product: Fresh Snow Peas (1,000/10 lb. cases)

Sue Ng, President
Snow Peas International, Inc.
1480 N.W. 96th Avenue
Miami, Florida 33172

Dear Ms. Ng:

The Food and Drug Administration (FDA) on August 31, 2001, attempted to supervise the destruction of the above refused entry of snow peas which was offered for entry into the United States by your firm. The following chart gives background information for this entry:

Entry No.

Entry Date


Date Refusal Notice



1,000/10 lb. Cases


Our examination of the product referenced above and presented for destruction indicate that the snow peas presented for destruction do not appear to be the product which was originally entered. The majority of the product presented for the destruction contained low quality snow peas with pieces of stems and leaves (calyx) and, to a lesser extent, sugar snap peas, mixed in with product. Review of entry documents indicate that calyx and sugar snap peas were not declared in the original entry.

As a result of our findings, we have recommended that the U. S. Customs Service (Customs) require that future entries of food by your firm be held in secured storage.

Secured storage will be under the supervision and direction of Customs, such as in a bonded warehouse. You will be responsible for all costs incurred at secured storage.

In addition, we are requesting Customs to order redelivery of this shipment. We request a response in writing within fifteen (15) working days of receipt of this letter outlining the specific steps you have taken to correct the violation, including an explanation of each step being taken to prevent recurrence. In the event that the product is still available for examination, you should inform Customs and FDA if and when redelivery is accomplished.

Your written reply should be addressed to the Food and Drug Administration, Attention: Paul R. Bagdikian, Compliance Officer, P.O. Box 59-2256, Miami, Florida 33159-2256.

Emma R. Singleton
Director, Florida District